ALX Oncology Announces Data from ASPEN-01, ALX148 Demonstrates Robust Objective Response in Patients | ALXO Message Board Posts


ALX Oncology Holdings Inc.

  ALXO website

ALXO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  6 of 11  at  7/17/2021 11:49:04 AM  by

jerrykrause


ALX Oncology Announces Data from ASPEN-01, ALX148 Demonstrates Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

 Pharma & Healthcare Monitor Worldwide
 

ALX Oncology Announces Data from ASPEN-01, ALX148 Demonstrates Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

 
 

ALX Oncology presented updated clinical data from its ongoing ASPEN-01 trial evaluating ALX148 in combination with trastuzumab and chemotherapy for the treatment of gastric or gastroesophageal junction cancer (GC). The data show that ALX148 in combination with trastuzumab and chemotherapy is highly active and well-tolerated in patients with second-line or greater (>2L) HER2 positive GC. These results were shared in an oral presentation at the 23rd World Congress on Gastrointestinal Cancer.

As of the data cut-off of May 3, 2021, 18 patients had been treated with either 10 mg/kg or 15 mg/kg of ALX148 once weekly with standard dosing regimens of trastuzumab, ramucirumab, and paclitaxel. In patients with >2L HER2 positive GC, whose tumors have progressed upon prior trastuzumab therapy, ALX148 demonstrated a promising initial confirmed objective response rate of 72% and estimated overall survival at 12 months of 76%. No maximum tolerated dose reached. The maximum administered dose of ALX148 in combination was 15 mg/kg once weekly. 2021 Global Data Point.

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...